Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In this cessation study, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765311/
https://www.ncbi.nlm.nih.gov/pubmed/29058817
http://dx.doi.org/10.1111/cas.13430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765311/
https://www.ncbi.nlm.nih.gov/pubmed/29058817
http://dx.doi.org/10.1111/cas.13430

Ejemplares similares